FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1950536611> ?p ?o ?g. }

• W1950536611 endingPage "1802" @default.
• W1950536611 startingPage "1796" @default.
• W1950536611 abstract "Expression of the multidrug resistance gene (MDR1) p170 protein is frequent in leukemic blasts from patients with relapsed acute myelogenous leukemia (AML). A phase I study using the nonimmunosuppressive MDR1 blocker SDZ PSC-833 (PSC) in combination with mitoxantrone (MITO) and etoposide (VP) was performed.Starting doses (LVL0) of MITO (3.25 mg/m2/d on days 1 and 3 to 6) and VP (210 mg/m2/d on days 1 and 3 to 5) were 40% of the maximal-tolerated dose (MTD) from a prior study. A 1.5-mg/kg loading dose of PSC was followed by a 120-hour continuous infusion of 10 mg/kg/d on days 2 to 6. Blood samples for PSC, MITO, and VP pharmacokinetics (PK) were taken on days 1 and 3, and samples for MDR1 expression were taken on day 0.Severe mucositis developed in all patients at LVL0; therefore, MITO and VP doses were reduced to 2.5 and 170 mg/m2 (LVL-1) for the next seven patients, and this dose proved to be MTD. All LVL0 and three LVL-1 patients had transient elevations in the serum bilirubin level to > or = 4 mg/dL. Serum creatinine level increased to greater than 2 mg/dL in one case. There were no other grade 3 or 4 nonhematologic toxicities observed. The peripheral blood was cleared of leukemia in three LVL0 and four LVL-1 patients. The marrow was cleared of leukemic cells in one LVL0 and five LVL-1 patients, and a significant reduction in marrow leukemic infiltrate was observed in eight of 10. No patient achieved complete remission (CR), and all died of progressive disease (n = 8) or infection (n = 2). MDR1 expression was detected by fluorescent-activated cell sorter (FACS) analysis in five of seven cases. An elevated MDR1 mRNA level was detected by quantitative polymerase chain reaction (Q-PCR) in six of eight cases studied. Clearing of leukemia cells from the marrow occurred in four of six MDR1-positive and one of three MDR1-negative patients. Despite the fact that LVL0 doses had to be reduced due to toxicity, coadministration of PSC did not produce a consistent effect on MITO PK; however, it did repeatedly lead to increased levels of VP in the serum.We conclude that PSC-MITO-VP is a tolerable regimen with antileukemic activity. Addition of PSC necessitated a 66% reduction in MITO and VP doses from a prior study without PSC." @default.
• W1950536611 created "2016-06-24" @default.
• W1950536611 creator A5004888325 @default.
• W1950536611 creator A5013595883 @default.
• W1950536611 creator A5027575595 @default.
• W1950536611 creator A5040395885 @default.
• W1950536611 creator A5045579010 @default.
• W1950536611 creator A5045600804 @default.
• W1950536611 creator A5057782352 @default.
• W1950536611 creator A5057920623 @default.
• W1950536611 creator A5081477605 @default.
• W1950536611 creator A5083096702 @default.
• W1950536611 creator A5083929738 @default.
• W1950536611 creator A5086839893 @default.
• W1950536611 date "1997-05-01" @default.
• W1950536611 modified "2023-10-15" @default.
• W1950536611 title "Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia." @default.
• W1950536611 cites W132770729 @default.
• W1950536611 cites W1547342210 @default.
• W1950536611 cites W1723032639 @default.
• W1950536611 cites W1776168062 @default.
• W1950536611 cites W1816122400 @default.
• W1950536611 cites W1824030076 @default.
• W1950536611 cites W1925223276 @default.
• W1950536611 cites W1927327874 @default.
• W1950536611 cites W1984686364 @default.
• W1950536611 cites W2033542059 @default.
• W1950536611 cites W2034525338 @default.
• W1950536611 cites W2077753080 @default.
• W1950536611 cites W2079466396 @default.
• W1950536611 cites W2079763637 @default.
• W1950536611 cites W2088419541 @default.
• W1950536611 cites W2113214957 @default.
• W1950536611 cites W2255251268 @default.
• W1950536611 cites W2411444329 @default.
• W1950536611 cites W2466569700 @default.
• W1950536611 doi "https://doi.org/10.1200/jco.1997.15.5.1796" @default.
• W1950536611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9164187" @default.
• W1950536611 hasPublicationYear "1997" @default.
• W1950536611 type Work @default.
• W1950536611 sameAs 1950536611 @default.
• W1950536611 citedByCount "90" @default.
• W1950536611 countsByYear W19505366112012 @default.
• W1950536611 countsByYear W19505366112013 @default.
• W1950536611 countsByYear W19505366112015 @default.
• W1950536611 countsByYear W19505366112017 @default.
• W1950536611 countsByYear W19505366112018 @default.
• W1950536611 countsByYear W19505366112022 @default.
• W1950536611 crossrefType "journal-article" @default.
• W1950536611 hasAuthorship W1950536611A5004888325 @default.
• W1950536611 hasAuthorship W1950536611A5013595883 @default.
• W1950536611 hasAuthorship W1950536611A5027575595 @default.
• W1950536611 hasAuthorship W1950536611A5040395885 @default.
• W1950536611 hasAuthorship W1950536611A5045579010 @default.
• W1950536611 hasAuthorship W1950536611A5045600804 @default.
• W1950536611 hasAuthorship W1950536611A5057782352 @default.
• W1950536611 hasAuthorship W1950536611A5057920623 @default.
• W1950536611 hasAuthorship W1950536611A5081477605 @default.
• W1950536611 hasAuthorship W1950536611A5083096702 @default.
• W1950536611 hasAuthorship W1950536611A5083929738 @default.
• W1950536611 hasAuthorship W1950536611A5086839893 @default.
• W1950536611 hasConcept C112705442 @default.
• W1950536611 hasConcept C126322002 @default.
• W1950536611 hasConcept C2776694085 @default.
• W1950536611 hasConcept C2776863199 @default.
• W1950536611 hasConcept C2778119113 @default.
• W1950536611 hasConcept C2778461978 @default.
• W1950536611 hasConcept C2778496288 @default.
• W1950536611 hasConcept C2780923524 @default.
• W1950536611 hasConcept C71924100 @default.
• W1950536611 hasConcept C90924648 @default.
• W1950536611 hasConcept C98274493 @default.
• W1950536611 hasConceptScore W1950536611C112705442 @default.
• W1950536611 hasConceptScore W1950536611C126322002 @default.
• W1950536611 hasConceptScore W1950536611C2776694085 @default.
• W1950536611 hasConceptScore W1950536611C2776863199 @default.
• W1950536611 hasConceptScore W1950536611C2778119113 @default.
• W1950536611 hasConceptScore W1950536611C2778461978 @default.
• W1950536611 hasConceptScore W1950536611C2778496288 @default.
• W1950536611 hasConceptScore W1950536611C2780923524 @default.
• W1950536611 hasConceptScore W1950536611C71924100 @default.
• W1950536611 hasConceptScore W1950536611C90924648 @default.
• W1950536611 hasConceptScore W1950536611C98274493 @default.
• W1950536611 hasIssue "5" @default.
• W1950536611 hasLocation W19505366111 @default.
• W1950536611 hasLocation W19505366112 @default.
• W1950536611 hasOpenAccess W1950536611 @default.
• W1950536611 hasPrimaryLocation W19505366111 @default.
• W1950536611 hasRelatedWork W146710521 @default.
• W1950536611 hasRelatedWork W165864744 @default.
• W1950536611 hasRelatedWork W1978721469 @default.
• W1950536611 hasRelatedWork W2027869118 @default.
• W1950536611 hasRelatedWork W2406279836 @default.
• W1950536611 hasRelatedWork W2478496593 @default.
• W1950536611 hasRelatedWork W36309184 @default.
• W1950536611 hasRelatedWork W4229791987 @default.
• W1950536611 hasRelatedWork W4242644534 @default.
• W1950536611 hasRelatedWork W2741778283 @default.

• next